Zhejiang Starry Pharm Co Ltd (603520) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) has a cash flow conversion efficiency ratio of 0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥9.76 Million ≈ $1.43 Million USD) by net assets (CN¥2.61 Billion ≈ $381.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zhejiang Starry Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Zhejiang Starry Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 603520 total liabilities for a breakdown of total debt and financial obligations.
Zhejiang Starry Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Starry Pharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trilogy Metals Inc
TO:TMQ
|
-0.005x |
|
Shenzhen Longtech Smart Control Co. Ltd.
SHE:300916
|
N/A |
|
Santacruz Silv
V:SCZ
|
0.125x |
|
Huayi Brothers Media Corp
SHE:300027
|
0.002x |
|
Janux Therapeutics Inc
NASDAQ:JANX
|
-0.013x |
|
Zhejiang Reclaim Construction Group Co Ltd
SHE:002586
|
-0.029x |
|
Crossamerica Partners LP
NYSE:CAPL
|
-0.409x |
|
Hainan Expressway Co Ltd
SHE:000886
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Zhejiang Starry Pharm Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Zhejiang Starry Pharm Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 603520 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.63 Billion ≈ $385.50 Million |
CN¥193.50 Million ≈ $28.32 Million |
0.073x | +180.09% |
| 2023-12-31 | CN¥1.76 Billion ≈ $257.38 Million |
CN¥46.13 Million ≈ $6.75 Million |
0.026x | +159.27% |
| 2022-12-31 | CN¥1.77 Billion ≈ $259.18 Million |
CN¥-78.37 Million ≈ $-11.47 Million |
-0.044x | -119.26% |
| 2021-12-31 | CN¥2.21 Billion ≈ $324.06 Million |
CN¥508.84 Million ≈ $74.46 Million |
0.230x | +145.57% |
| 2020-12-31 | CN¥1.86 Billion ≈ $272.87 Million |
CN¥174.48 Million ≈ $25.53 Million |
0.094x | -60.99% |
| 2019-12-31 | CN¥1.03 Billion ≈ $150.53 Million |
CN¥246.77 Million ≈ $36.11 Million |
0.240x | +15.41% |
| 2018-12-31 | CN¥922.96 Million ≈ $135.06 Million |
CN¥191.84 Million ≈ $28.07 Million |
0.208x | +901.60% |
| 2017-12-31 | CN¥872.44 Million ≈ $127.67 Million |
CN¥18.10 Million ≈ $2.65 Million |
0.021x | +123.47% |
| 2016-12-31 | CN¥827.01 Million ≈ $121.02 Million |
CN¥7.68 Million ≈ $1.12 Million |
0.009x | -95.52% |
| 2015-12-31 | CN¥457.70 Million ≈ $66.98 Million |
CN¥94.88 Million ≈ $13.88 Million |
0.207x | -37.79% |
| 2014-12-31 | CN¥432.13 Million ≈ $63.23 Million |
CN¥144.00 Million ≈ $21.07 Million |
0.333x | +71.57% |
| 2013-12-31 | CN¥386.11 Million ≈ $56.50 Million |
CN¥74.99 Million ≈ $10.97 Million |
0.194x | -36.70% |
| 2012-12-31 | CN¥336.81 Million ≈ $49.29 Million |
CN¥103.34 Million ≈ $15.12 Million |
0.307x | +325.46% |
| 2011-12-31 | CN¥301.81 Million ≈ $44.16 Million |
CN¥-41.07 Million ≈ $-6.01 Million |
-0.136x | -- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more